John F. Flaherty

10.1k total citations · 1 hit paper
136 papers, 5.6k citations indexed

About

John F. Flaherty is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, John F. Flaherty has authored 136 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Epidemiology, 75 papers in Hepatology and 43 papers in Infectious Diseases. Recurrent topics in John F. Flaherty's work include Hepatitis B Virus Studies (76 papers), Hepatitis C virus research (73 papers) and Liver Disease Diagnosis and Treatment (44 papers). John F. Flaherty is often cited by papers focused on Hepatitis B Virus Studies (76 papers), Hepatitis C virus research (73 papers) and Liver Disease Diagnosis and Treatment (44 papers). John F. Flaherty collaborates with scholars based in United States, Canada and France. John F. Flaherty's co-authors include Patrick Marcellin, Brian P. Kearney, Kathryn M. Kitrinos, Edward Gane, G. Mani Subramanian, Marı́a Buti, Jaymin Shah, John G. McHutchison, Raul Aguilar Schall and Ira M. Jacobson and has published in prestigious journals such as The Lancet, Journal of Personality and Social Psychology and Gastroenterology.

In The Last Decade

John F. Flaherty

123 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

2012 1.3k citations Patrick Marcellin, Edward Gane et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John F. Flaherty United States	37	3.7k	3.0k	1.7k	647	346	136	5.6k
David C. Perlman United States	32	2.4k 0.7×	557 0.2×	1.8k 1.1×	148 0.2×	88 0.3×	171	3.7k
Josep Mallolas Spain	40	2.3k 0.6×	1.5k 0.5×	3.2k 1.9×	1.5k 2.4×	1.1k 3.1×	224	5.5k
Elisa de Lazzari Spain	32	1.6k 0.4×	493 0.2×	2.2k 1.3×	1.1k 1.7×	791 2.3×	105	3.7k
Shinichi Oka Japan	45	2.8k 0.8×	678 0.2×	4.3k 2.5×	3.2k 5.0×	879 2.5×	475	8.1k
Sandro Vento Italy	31	1.9k 0.5×	1.6k 0.5×	738 0.4×	191 0.3×	87 0.3×	127	3.6k
Charles van der Horst United States	29	2.0k 0.5×	722 0.2×	2.3k 1.4×	725 1.1×	597 1.7×	79	3.7k
Donna Mildvan United States	45	3.9k 1.1×	522 0.2×	5.3k 3.2×	3.7k 5.8×	1000 2.9×	130	9.6k
Marina B. Klein Canada	47	3.6k 1.0×	2.7k 0.9×	2.7k 1.6×	1.1k 1.7×	916 2.6×	288	6.6k
Markus Flepp Switzerland	33	2.0k 0.6×	789 0.3×	4.1k 2.4×	2.8k 4.3×	1.0k 3.0×	74	5.6k
Maria Jesús Pérez‐Elías Spain	29	1.1k 0.3×	499 0.2×	2.4k 1.4×	1.7k 2.6×	786 2.3×	179	3.4k

Countries citing papers authored by John F. Flaherty

Since Specialization

Citations

This map shows the geographic impact of John F. Flaherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Flaherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Flaherty more than expected).

Fields of papers citing papers by John F. Flaherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Flaherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Flaherty. The network helps show where John F. Flaherty may publish in the future.

Co-authorship network of co-authors of John F. Flaherty

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Flaherty. A scholar is included among the top collaborators of John F. Flaherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Flaherty. John F. Flaherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lampertico, Pietro, Pavel Bogomolov, Vladimir Chulanov, et al.. (2025). Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐IFNα‐2a as Treatment for Chronic Hepatitis Delta. Liver International. 45(2). e70008–e70008. 3 indexed citations

Wong, Grace Lai–Hung, Edward Gane, Calvin Q. Pan, et al.. (2025). Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment. Alimentary Pharmacology & Therapeutics. 63(1). 132–144.

Allweiss, Lena, Vithika Suri, Jeffrey J. Wallin, et al.. (2024). Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies. Journal of Hepatology. 80(6). 882–891. 18 indexed citations

Buti, Marı́a, Heiner Wedemeyer, Soo Aleman, et al.. (2024). Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide. Journal of Hepatology. 82(1). 28–36. 7 indexed citations

Asselah, Tarik, Pietro Lampertico, Soo Aleman, et al.. (2024). Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Liver International. 45(4). e16174–e16174. 5 indexed citations

Fung, Scott, Calvin Q. Pan, Grace Lai–Hung Wong, et al.. (2023). Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks. Alimentary Pharmacology & Therapeutics. 59(2). 217–229. 7 indexed citations

Lim, Young‐Suk, W. Ray Kim, Douglas T. Dieterich, et al.. (2023). Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B. Viruses. 15(4). 997–997. 15 indexed citations

Allweiss, Lena, Vithika Suri, Jeffrey J. Wallin, et al.. (2023). Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301. Zeitschrift für Gastroenterologie. 61(1). e50–e51. 1 indexed citations

Kim, W. Ray, Laura Telep, Belinda Jump, et al.. (2022). Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Alimentary Pharmacology & Therapeutics. 55(7). 828–835. 8 indexed citations

10.

Lim, Young‐Suk, Wai‐Kay Seto, Masayuki Kurosaki, et al.. (2022). Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. Alimentary Pharmacology & Therapeutics. 55(8). 921–943. 19 indexed citations

11.

Lim, Young‐Suk, Chun‐Yen Lin, Jeong Heo, et al.. (2021). IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2. A77.1–A77. 1 indexed citations

12.

Ahn, Sang Hoon, Jia‐Horng Kao, Hie‐Won Hann, et al.. (2020). IDDF2020-ABS-0058 48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV asian patients with TDF risk factors (RF). Abstracts. A73.3–A74. 1 indexed citations

13.

Podlaha, Ondřej, Edward Gane, Maurizia Rossana Brunetto, et al.. (2019). Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. Scientific Reports. 9(1). 10529–10529. 15 indexed citations

14.

Chan, Henry Lik‐Yuen, Wai Kay Seto, Marı́a Buti, et al.. (2019). IDDF2019-ABS-0168 Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). A141.2–A141. 2 indexed citations

15.

Chan, Henry Lik‐Yuen, Marı́a Buti, Robert Flisiak, et al.. (2018). IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). A97.1–A97. 2 indexed citations

16.

Brunetto, Maurizia Rossana, Aric J. Hui, Rajiv Mehta, et al.. (2018). IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB). A97.2–A98. 1 indexed citations

17.

Fung, Scott, Stuart C. Gordon, Zahary Krastev, et al.. (2014). Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log₁₀ copies/ml). Liver International. 35(2). 422–428. 4 indexed citations

18.

Chan, Henry Lik‐Yuen, Marı́a Buti, Patrick Marcellin, et al.. (2013). 761 COMPARISON OF SERUM HBsAg DECLINES DURING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN DIFFERENT CHRONIC HEPATITIS B (CHB) SUB-POPULATIONS. Journal of Hepatology. 58. S309–S310. 2 indexed citations

19.

Holtzer, Christopher, John F. Flaherty, & Rebecca Coleman. (1998). Cross‐Reactivity in HIV‐infected Patients Switched from Trimethoprim‐Sulfamethoxazole to Dapsone. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(4). 831–835. 21 indexed citations

20.

Flaherty, John F., et al.. (1970). Peter Drucker : contributions to business enterprise. New York University Press eBooks. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact